# Shenzhen Shinesky Biological Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-shinesky-biological-technology-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.shineskychina.com
- Total disclosed funding: $45M
- Latest round: Series C (Apr 16, 2025)
- Investors on record: 7

## About

Founded in 2017 and based in Shenzhen, China, Shenzhen Shinesky Biological Technology Co., Ltd., is a biological company that focuses on supramolecular science and natural ionic liquid technology. The company has applied for more than two hundred national applications for patents. It has industrial parks and plants in Shaoguan, Foshan, Zhuhai, Heyuan, Zunyi, Wenzhou, and Kunming. Five subsidiary companies were established for raw material manufacture, development center, products processing base, operation center and financial services business. The company has passed the ISO9001 quality management system certification. It won the national high-tech enterprise certification, Shaoguan City 2021 Science and Technology Achievement Award, and 2022 Ringier Technology Innovation Award. Shenzhen Shinesky Biological Technology Co., Ltd. has cooperated with Estee Lauder, L’ORÉAL, HomeFacialPro and other enterprises at home and abroad. In April 2025, it raised approximately CNY 100 million in series C funding led by new investor YuanBio Venture. The company’s main business is providing one-stop CDMO services and material modification solutions through its proprietary supramolecular intelligent assembly technology. The company’s self-developed products include functional ingredients such as supramolecular salicylic acid, carnosine, glycerin glucoside, and SynthrixJIM, an AI-driven supramolecular synthesis platform. Its products are used in the fields of cosmetics, biomedicine, functional foods, agriculture, environmental protection, and new energy. Shenzhen Shinesky Biological Technology Co., Ltd. generates revenue by providing customized CDMO services, patented ingredient licensing, and technology solutions. The company will use the series C funding to upgrade the AI ??research and development platform for supramolecular new materials, develop safe electrolytes, recycle used batteries, and recycle silver powder for photovoltaic silicon panels.

## Funding rounds

- Series C, Apr 16, 2025, $14M — YuanBio Venture
- Series A, Jun 24, 2022, $30M — Oriental Fortune Capital, Hongtai Fund, Bloomage Biotechnology Corporation, Qianhai Sihai New Material Capital, Tongchuang Weiye
- Series A, Jan 30, 2021, $1.6M — Goofar Sanxin Fund

## Investors

- Goofar Sanxin Fund (https://capitalatlas.ai/funds/goofar-sanxin-fund) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Hongtai Fund (https://capitalatlas.ai/funds/hongtai-fund) — Series A
- Bloomage Biotechnology Corporation — Series A
- Qianhai Sihai New Material Capital (https://capitalatlas.ai/funds/qianhai-sihai-new-material-capital) — Series A
- Tongchuang Weiye — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C